Table 4.
Sensitivity analysis of positive PT signals following missing data removal.
| PT | a | ROR (95%Cl) | PRR (χ2) | EBGM (EBGM05) | IC (IC-2SD) |
|---|---|---|---|---|---|
| Age | |||||
| INJECTION SITE ERYTHEMA | 22827 | 3.63 (3.58 - 3.68) |
3.52 (33689.15) |
3.03 (3.00) |
1.60 (1.58) |
| ERYTHEMA | 16436 | 3.59 (3.53 - 3.65) |
3.51 (24115.71) |
3.03 (2.99) |
1.60 (1.57) |
| INJECTION SITE SWELLING | 16381 | 3.53 (3.47 - 3.59) |
3.45 (23346.10) |
2.99 (2.94) |
1.58 (1.55) |
| INJECTION SITE PAIN | 16151 | 2.35 (2.31 - 2.39) |
2.31 (10484.61) |
2.13 (2.10) |
1.09 (1.07) |
| INJECTION SITE WARMTH | 8652 | 3.10 (3.03 - 3.17) |
3.07 (10032.39) |
2.71 (2.66) |
1.44 (1.40) |
| CRYING | 5702 | 7.23 (7.01 - 7.47) |
7.17 (20421.31) |
5.15 (5.02) |
2.37 (2.32) |
| PERIPHERAL SWELLING | 5615 | 2.58 (2.51 - 2.66) |
2.57 (4589.62) |
2.33 (2.28) |
1.22 (1.18) |
| SWELLING | 5412 | 2.62 (2.55 - 2.70) |
2.61 (4581.18) |
2.37 (2.31) |
1.24 (1.20) |
| SKIN WARM | 5409 | 3.62 (3.52 - 3.73) |
3.60 (8178.86) |
3.09 (3.01) |
1.63 (1.58) |
| CELLULITIS | 4654 | 6.87 (6.63 - 7.11) |
6.82 (15843.13) |
4.98 (4.84) |
2.32 (2.27) |
| Administration dose | |||||
| INJECTION SITE ERYTHEMA | 15823 | 4.37 (4.29 - 4.44) |
4.22 (34419.04) |
3.82 (3.76) |
1.93 (1.91) |
| INJECTION SITE SWELLING | 10999 | 4.09 (4.00 - 4.17) |
3.99 (21911.56) |
3.64 (3.57) |
1.86 (1.83) |
| ERYTHEMA | 10854 | 3.89 (3.81 - 3.97) |
3.81 (20037.8) |
3.48 (3.42) |
1.80 (1.77) |
| INJECTION SITE PAIN | 10429 | 2.63 (2.57 - 2.68) |
2.58 (9388.74) |
2.45 (2.41) |
1.29 (1.26) |
| INJECTION SITE WARMTH | 5928 | 3.78 (3.67 - 3.88) |
3.73 (10565.35) |
3.42 (3.35) |
1.78 (1.74) |
| CRYING | 4708 | 9.43 (9.13 - 9.75) |
9.33 (26613.31) |
7.32 (7.12) |
2.87 (2.82) |
| IRRITABILITY | 3833 | 13.14 (12.64 - 13.65) |
13.01 (29483.11) |
9.32 (9.03) |
3.22 (3.17) |
| PERIPHERAL SWELLING | 3578 | 2.48 (2.40 - 2.57) |
2.47 (2891.4) |
2.35 (2.29) |
1.23 (1.18) |
| SKIN WARM | 3542 | 4.14 (4.00 - 4.29) |
4.11 (7340.98) |
3.73 (3.62) |
1.90 (1.85) |
| SWELLING | 3500 | 2.68 (2.59 - 2.77) |
2.66 (3338.88) |
2.52 (2.45) |
1.33 (1.28) |
| Clinical outcome | |||||
| INJECTION SITE ERYTHEMA | 12636 | 3.20 (3.14 - 3.26) |
3.13 (16624.74) |
2.91 (2.87) |
1.54 (1.52) |
| ERYTHEMA | 9206 | 3.07 (3 - 3.13) |
3.02 (11313.26) |
2.82 (2.77) |
1.50 (1.47) |
| INJECTION SITE SWELLING | 9047 | 3.11 (3.04 - 3.18) |
3.06 (11401.05) |
2.86 (2.80) |
1.51 (1.48) |
| CRYING | 5021 | 9.81 (9.5 - 10.13) |
9.69 (29131.17) |
7.46 (7.26) |
2.90 (2.85) |
| INJECTION SITE WARMTH | 4376 | 2.56 (2.48 - 2.64) |
2.54 (3771.93) |
2.41 (2.35) |
1.27 (1.23) |
| IRRITABILITY | 3451 | 10.79 (10.37 - 11.22) |
10.70 (21981.65) |
8.02 (7.76) |
3.00 (2.95) |
| CELLULITIS | 3118 | 6.23 (5.99 - 6.48) |
6.19 (11124.41) |
5.25 (5.08) |
2.39 (2.34) |
| SWELLING | 3068 | 2.21 (2.13 - 2.29) |
2.20 (1868.44) |
2.11 (2.05) |
1.08 (1.02) |
| INJECTION SITE OEDEMA | 3028 | 4.34 (4.18 - 4.51) |
4.32 (6696.75) |
3.87 (3.75) |
1.95 (1.90) |
| OEDEMA PERIPHERAL | 2870 | 4.24 (4.08 - 4.41) |
4.22 (6140.17) |
3.80 (3.68) |
1.93 (1.87) |
PT, preferred term; CI, confidence interval; ROR, reporting odds ratio; PRR, proportional reporting ratio; χ2, Chi-squared; IC, information component; IC-2SD, the lower limit of the 95% two-sided CI of the IC; EBGM, empirical Bayesian geometric mean; EBGM05, the lower 95 two-sided CI of EBGM.